Bausch & Lomb sale

Bausch & Lomb, the eye care company, has agreed to be sold to the Canadian healthcare company Valeant Pharmaceuticals for about $US8.7 billion ($9 billion). Valeant will pay $US4.5 billion to the investor group that owns B&L, led by private equity firm Warburg Pincus. It will also spend about $US4.2 billion to repay B&L's debt.

Bausch & Lomb, the eye care company, has agreed to be sold to the Canadian healthcare company Valeant Pharmaceuticals for about $US8.7 billion ($9 billion). Valeant will pay $US4.5 billion to the investor group that owns B&L, led by private equity firm Warburg Pincus. It will also spend about $US4.2 billion to repay B&L's debt.